Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, Helios Klinikum Berlin-Buch, Academic Teaching Hospital of the Charité Universitätsmedizin, Berlin.
Pediatrics 5-Oncology, Hematology and Immunology, COSS Study Center, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany.
Ann Oncol. 2011 May;22(5):1228-1235. doi: 10.1093/annonc/mdq589. Epub 2010 Oct 28.
Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate which factors correlate with LR in patients who achieved complete surgical remission with adequate margins.
We analyzed 1355 patients with previously untreated high-grade central osteosarcoma of the extremities, the shoulder and the pelvis registered in neoadjuvant Cooperative Osteosarcoma Study Group trials between 1986 and 2005. Seventy-six patients developed LR.
Median follow-up was 5.56 years. No participation in a study, pelvic tumor site, limb-sparing surgery, soft tissue infiltration beyond the periosteum, poor response to neoadjuvant chemotherapy, failure to complete the planned chemotherapy protocol and biopsy at a center other than the one performing the tumor resection were significantly associated with a higher LR rate. No differences were found for varying surgical margin widths. Surgical treatment at centers with small patient volume and additional surgery in the primary tumor area, other than biopsy and tumor resection, were significantly associated with a higher rate of ablative surgery.
Patient enrollment in clinical trials and performing the biopsy at experienced institutions capable of undertaking the tumor resection without compromising the oncological and functional outcome should be pursued in the future.
骨肉瘤的局部复发与非常差的预后相关。我们试图评估在达到完全手术缓解且切缘足够的患者中,哪些因素与局部复发相关。
我们分析了 1986 年至 2005 年期间新辅助合作骨肉瘤研究组试验中登记的 1355 例先前未经治疗的四肢、肩部和骨盆高级别中心性骨肉瘤患者。76 例患者发生局部复发。
中位随访时间为 5.56 年。未参与研究、骨盆肿瘤部位、保肢手术、骨膜外软组织浸润、对新辅助化疗的反应不良、未能完成计划的化疗方案以及在除进行肿瘤切除的中心之外的其他中心进行活检与更高的局部复发率显著相关。手术切缘宽度的变化与局部复发率无差异。在患者数量较少的中心进行手术治疗,以及在除活检和肿瘤切除之外的原发性肿瘤区域进行额外手术,与根治性手术的更高发生率显著相关。
未来应追求将患者纳入临床试验,并在有经验的机构进行活检,这些机构有能力在不影响肿瘤学和功能结果的情况下进行肿瘤切除。